ArticleOncotarget2017
Epidemiology and survival outcome of breast cancer in a nationwide study.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- 5-year survival rate and determinants of decreased survival among patients with breast cancer in Africa: a systematic review and meta-analysis.BMJ global health · 2026Pooled it
- Predictors of survival rates among breast cancer patients in Ethiopia: a systematic review and meta-analysis 2024.Archives of public health = Archives belges de sante publique · 2025Article
- Molecular Mechanism of Breast Cancer and Predisposition of Mouse Mammary Tumor Virus Propagation Cycle.Current medicinal chemistry · 2025Review
- Unveiling the comorbidity burden of male breast cancer.Scientific reports · 2024Observational
- High-protein diet scores, macronutrient substitution, and breast cancer risk: insights from substitution analysis.BMC women's health · 2024Article
- Utility of FDG PET/CT in Patient with Synchronous Breast and Colon Cancer.Diagnostics (Basel, Switzerland) · 2023Article
- The Use of San-Huang-Xie-Xin-Tang Reduces the Mortality Rate among Breast Cancer Patients.Cancers · 2023Article
- The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis.Breast cancer research and treatment · 2023Article
- Risk of Breast Cancer Progression after Treatment in the Western Region of Saudi Arabia.Breast cancer : basic and clinical research · 2023Article
- Chemopreventive effects of Xiang Sha Liu Jun Zi Tang on paclitaxel-induced leucopenia and neuropathy in animals.Frontiers in pharmacology · 2023Article
- Mammographic breast density status in women aged more than 40 years in Sulaimaniyah, Iraq: a cross-sectional study.The Journal of international medical research · 2022Article
- NRBP1 negatively regulates SALL4 to reduce the invasion and migration, promote apoptosis and increase the sensitivity to chemotherapy drugs of breast cancer cells.Oncology letters · 2022Article
- PCDHB15 as a potential tumor suppressor and epigenetic biomarker for breast cancer.Oncology letters · 2022Article
- Revisiting the MMTV Zoonotic Hypothesis to Account for Geographic Variation in Breast Cancer Incidence.Viruses · 2022Article
- The current status of risk-stratified breast screening.British journal of cancer · 2022Review
- Perioperative Risk Factors for Prolonged Blood Loss and Drainage Fluid Secretion after Breast Reconstruction.Journal of clinical medicine · 2022Article
- Clinicopathological characteristics and treatment outcomes of luminal B1 breast cancer in Taiwan.Journal of the Chinese Medical Association : JCMA · 2022Observational
- Treatment Outcomes and Its Associated Factors Among Adult Patients with Selected Solid Malignancies at Kenyatta National Hospital: A Hospital-Based Prospective Cohort Study.Cancer management and research · 2022Article
- Trends in Breast Cancer Incidence in Iraq During the Period 2000-2019.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Pharmacological inhibition of MDA-9/Syntenin blocks breast cancer metastasis through suppression of IL-1β.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is among the most prevalent cancers in Taiwan. The National Health Insurance database was used to identify patients with breast cancer and estimate the yearly prevalence and incidence of breast cancer between 1997 and 2013. Joinpoint regression analysis was used for the annual percentage change of incidence, prevalence, and survival outcome. Among 12,181,919 female beneficiaries in 2013, the prevalence was 834.37 per 100,000 persons (95% confidence interval, 829.28-839.45) and the incidence was 93.00 per 100,000 person-year (95% confidence interval, 91.27-94.73). The average annual percentage change of the age-standardized breast cancer incidence was 3.5 per 100,000 person-years (3.1-3.8; P < 0.05), suggesting an increase in breast cancer incidence over the study period. The 5-year mortality rate was 4.5% in 1997 and 4.4% in 2008. The 5-year mortality rate among patients with Charlson comorbidity index > 1 was 39.1% (19.2%-59.1%) in 1997 and 21.1% (15.7%-32.0%) in 2008, with an annual percentage change of -0.8 (-1.3 to 2.9), suggesting that the mortality rate was gradually decreasing in patients with comorbidities. In conclusion, 1 in 120 women in Taiwan has breast cancer and the incidence is rising, while the annual percentage change of breast cancer prevalence is decreasing. The mortality rate of breast cancer was essentially stable, but the 1-year, 2-year, and 5-year mortality rates in people with Charlson comorbidity index > 1 were declined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.